A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1359-1368

  Liu, Na ^a   Cui, Rui Xue ^a   Sun, Ying ^a   Guo, Rui ^a   Mao, Yan Ping ^a   Tang, Ling Long ^a   Jiang, Wei ^a   Liu, Xu ^a   Cheng, Yi Kan ^a   He, Qing Mei ^a   Cho, William C S ^b   Liu, Li Zhi ^a   Li, Li ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

biomarkers; microRNA; nasopharyngeal carcinoma; prognosis; serum

Indexed keywords

MICRORNA; MICRORNA 1234; MICRORNA 22; MICRORNA 572; MICRORNA 638; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCORING SYSTEM;

EID: 84891836332     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28468     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Cuardo MP, Edwards BK, Shin HR, et al. Cancer incidence in five continents, vol. IX. Lyon, France: International Agency for Research on Cancer, 2007.
3. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual, 7th edn. New York: Springer, 2010.
4. Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 73: 1326-34.
5. Edge SB, Compton CC,. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4.
6. Tsang LC, Lo YM,. Circulating nucleic acids in plasma/serum. Pathology 2007; 39: 197-207.
7. Lo YM, Tsui NB, Chiu RW, et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med 2007; 13: 218-23.
8. Swarup V, Rajeswari RM,. Circulating (cell-free) nucleic acids-a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007; 581: 795-9.
9. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-18.
10. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
11. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
12. Pigati L, Yaddanapudi SC, Lyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515.
13. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracelluar environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010; 5: e13247.
14. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-7.
15. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
16. Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-8.
17. Zhao H, Shen J, Medico L, et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010; 5: e13735.
18. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28: 1721-6.
19. Zuo Z, Calin GA, de Paula HM, et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011; 118: 413-15.
20. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6: e17745.
21. Sengupta S, den Boon JA, Chen IH, et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105: 5874-8.
22. Chen HC, Chen GH, Chen YH, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009; 100: 1002-11.
23. Liu N, Chen NY, Cui R, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012; 13: 633-41.
24. Zeng X, Xiang J, Wu M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 2012; 7: e46367.
25. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-44.
26. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
27. Chow SC, Shao J, Wang HS,. Sample size calculations in clinical research. New York: Marcel Dekker, 2003.
28. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-37.
29. Yang HI, Yuen MF, Chan HL, et al.; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-74.
30. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12-22.
31. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004; 60: 1440-50.
32. Hui EP, Leung SF, Au JS, et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004; 101: 300-6.
33. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-9.
34. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23: 3568-76.
35. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73.
36. Kong YW, Ferland-McCollough D, Jackson TJ, et al. MicroRNAs in cancer management. Lancet Oncol 2012; 13: e249-e258.
37. Krützfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
38. Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
39. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-6.
40. Meckes DG, Jr, Shair KH, Marquitz AR, et al. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci USA 2010; 107: 20370-5.